PSYCHPSYCHPSYCH
  • REPORT
  • THE PSYCH SUMMIT
    • SPEAKERS
    • FEATURED COMPANIES
  • NEWS & INSIGHTS
  • NEWSLETTER
  • COMPANIES
  • REPORT
  • THE PSYCH SUMMIT
    • SPEAKERS
    • FEATURED COMPANIES
  • NEWS & INSIGHTS
  • NEWSLETTER
  • COMPANIES

THE PSYCHEDELICS NEWSLETTER

Our weekly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries. Subscribe for free now.

ISSUES

Issue 23

Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.

Issue 22

Four companies added to the world’s largest psychedelics exchange and adding Field Trip Health to the PSYCH Investor Summit: Europe and Asia. Learn more in Issue 22 of The Psychedelics Newsletter.

Issue 21

The Australian government has announced $15m of funding for psychedelic medicines in a boost to the domestic and international market. Learn more in Issue 21 of The Psychedelics Newsletter.

Issue 20

The first-ever ketamine-assisted psychotherapy clinic has opened in the UK while Field Trip Health has confirmed the closing of $95m of funding. All this and more in Issue 20 of The Psychedelics Newsletter.

Issue 19

Researchers have published the results of a global drug survey, revealing that the use of psychedelics to treat mental health conditions is increasing.

Issue 18

Researchers have published the results on the most comprehensive study on microdosing while European psychedelic companies have been given an edge in the international market.

Issue 17

The results of a study on the use of MDMA to treat alcohol addiction have been published this week, whilst reforms on the use of psychedelics continue to take shape across the US.

Issue 16

The PSYCH Investor Summit is now open for registration and you can apply for tickets in this week’s issue of our newsletter, which also includes the most important stories from across the industry.

Issue 15

The Psychedelics industry has hit a major milestone as a number of industry-leading businesses have been listed on a dedicated exchange, allowing shares to be traded freely.

Issue 14

PSYCH hits 25,000 subscribers to become industry’s fastest-growing newsletter while a number of major announcements on the advancement of research into psychedelic medicines have been made.

Issue 13

Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.

Issue 12

The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.

Issue 11

Gain access to every panel discussion from The PSYCH Symposium before time runs out and catch up on the latest news from across the international psychedelics industry in Issue 11 of The Psychedelics Newsletter, here.

Issue 10

The PSYCH Symposium is about to begin and only a limited number of places remain.
You can also catch up on all of the latest news from across the psychedelics industry, here.
 

Issue 09

The PSYCH Symposium is set to bring together leaders from across the international psychedelics industry who are set to discuss and debate the most important issues facing the sector.

Issue 08

With less than a month to go, there is only a limited amount of time to secure your place at The Psych Symposium. You can also catch up with the biggest news stories from across the industry, here.
 

Issue 07

Taking place 17-20 as part of Prohibition Partners LIVE, The PSYCH Symposium will bring together distinguished industry thought leaders, rising entrepreneurs and experienced policymakers.

Issue 06

The Psychedelics as Medicine Report: Second Edition has been launched by PSYCH. The report delivers a comprehensive overview of the entire psychedelics sector and can be accessed in this week’s issue.
 

Issue 05

An Oregonian Congressman supports a measure for the legalisation of psilocybin therapy and psychedelic decriminalisation awaits a response from the Canadian government.

Issue 04

A petition to legalise natural psychedelics in Canada reaches 13,000 signatures,  and a Congressman has said psychedelics show promise in treating PTSD as Oakland activists also unveil guidelines for psychedelic healing ceremonies.
 

Issue 03

Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.

Issue 02

An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.

Issue 01

Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions. 

THE LATEST INSIGHTS, STRAIGHT TO YOUR INBOX

Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.

+44 (0) 203 928 2814
20-22 Wenlock Road, London, N1 7GU, United Kingdom

 

©2021 PP Intelligence LTD. (t/a PSYCH)

Privacy Policy